
EIKN Stock Forecast & Price Target
EIKN Analyst Ratings
Bulls say
Eikon Therapeutics is a clinical stage biotechnology company with a dedicated focus on addressing serious unmet medical needs through the development of important medicines. The company's single operating segment, drug discovery, leverages its proprietary technology and clinical development of its product candidates, which include EIK1001, EIK1003, EIK1004, EIK1005, and EIK1006. With a strong pipeline and a commitment to innovation, the company is well-positioned for future growth and success in the biopharmaceutical industry.
Bears say
Eikon Therapeutics is a late-stage clinical biopharmaceutical company with a single operating segment focusing on drug discovery and clinical development of its product candidates, including EIK1001, EIK1003, EIK1004, EIK1005, and EIK1006. The company's financials for the first quarter showed a net loss of $79.7 million, and with current cash and equivalents expected to fund operations into 2H:27, it is crucial for the company to present positive clinical data for its pipeline assets in order to attain its $7 price target and avoid failure from competitor therapies.
This aggregate rating is based on analysts' research of Eikon Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.
EIKN Analyst Forecast & Price Prediction
Start investing in EIKN
Order type
Buy in
Order amount
Est. shares
0 shares